Man Group
KNTE

Man Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Man Group’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-33,473
Closed -$80.4K – 1804
2023
Q2 		$101K Buy
+33,473
New +$129K ﹤0.01% 1881

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Man Group's KNTE Position: Q3 2023 in Review

Man Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2023, closing a stake of 33,473 shares — an estimated $80.4K sold.

Man Group first reported a position in KNTE in Q2 2023 and held it in 1 quarter. The position peaked at $101K in Q2 2023. 58 funds tracked by Wall St. Rank hold KNTE as of Q3 2023.

  • Man Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Man Group sold 33,473 Kinnate Biopharma Inc. Common Stock shares in Q3 2023, an estimated $80.4K.
  • Man Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Man Group's Kinnate Biopharma Inc. Common Stock position peaked at $101K in Q2 2023.
  • 58 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.